Russia suspends registration of 'Decaris' over health risks
Russia has suspended the registration of the Hungarian anti-parasitic drug 'Decaris' due to health risks associated with its active ingredient, levamisole, with the suspension effective from September 1, 2026, and pending further information from the manufacturer.
Consensus
- The registration of the drug 'Decaris' produced by Hungarian company Gedeon Richter has been suspended in Russia.
- The suspension is due to a threat to human health from the active ingredient levamisole.
- The suspension became effective on September 1, 2026.
- The registration will not be restored until the manufacturer provides information to the Ministry of Health.
- The drug is available in tablet form with dosages of 50 mg and 150 mg.
- The international non-proprietary name of the drug is levamisole.
- The decision was based on a conclusion from Roszdravnadzor regarding health risks.
- The Ministry of Health cited Article 159 of the Rules for Registration and Expertise of Medicinal Products.
Points of divergence
- The suspension was due to the risk of brain damage. — vm
- The European Medicines Agency (EMA) has assessed the benefit-risk ratio of levamisole as unfavorable. — vesti
- The UAE has made a breakthrough in treating autoimmune skin diseases, becoming the first country to approve tablets for non-segmental vitiligo. — vesti
Coverage (5 sources)
- Registration of the drug against worms "Decaris" suspended in Russia — Вести
- Ministry of Health suspended registration of 'Decaris' due to risk of brain damage — Вечерняя Москва
- Ministry of Health of Russia suspended registration of Hungarian drug "Decaris" — Интерфакс
- Ministry of Health suspended registration of Hungarian drug 'Decaris' — Ведомости
- Ministry of Health suspended registration of Hungarian anti-helminthic drug "Decaris" due to threat to human health. This is follow... — ТАСС (Telegram)